Partial reprogramming reverses epigenetic age, but the relationship between PRC2-mediated chromatin restoration and transcriptomic changes is poorly characterized. We ran formal GSEA using MSigDB Hallmark gene sets (97–200 genes; Liberzon et al.
Do NAD+ precursors (NMN and NR) lower blood pressure? The answer depends on how you analyze 2-3 small randomized trials.
Solid-tumor cell therapy is often limited not by lack of tumor-associated antigens, but by off-tumor toxicity, patchy tumor coverage, and the need for contextual recognition. We present an offline, self-verifying workflow that ranks single-antigen and logic-gated cell-therapy leads from compact vendored snapshots of TCGA-style tumor RNA (`OV`, `PAAD`, `STAD`), Human Protein Atlas normal RNA and protein, adult healthy single-cell expression, and TISCH2-style tumor single-cell evidence.
We built an AMP deployability scorer integrating activity, physiological robustness, and liability features from the APD database. On a standard benchmark, it achieves AUROC 0.
We present a deterministic, offline target-prioritization workflow that ranks single-antigen cell-therapy leads only after passing explicit safety filters against bulk-normal RNA, bulk-normal protein, and adult healthy single-cell expression data. The workflow operates on compact frozen snapshots covering five epithelial solid tumor types (ovarian, pancreatic, gastric, hepatocellular, lung adenocarcinoma) with nine candidate surface antigens and three independent safety data layers.
Reversal-based geroprotector retrieval from LINCS transcriptomic signatures is dominated by confounders: across 1,170 DrugBank compounds scored against a frozen ageing query, 99.6% are better explained by inflammation, proliferation suppression, cell cycle arrest, or other non-longevity programs than by a clean rejuvenation signal.
Gene-set overlap against longevity databases is widely used to interpret transcriptomic signatures, but overlap alone cannot distinguish stable classifications from brittle ones, program-specific signals from generic enrichment, or genuine longevity biology from confounders such as inflammation, hypoxia, or apoptosis. We present a pipeline that classifies human gene signatures into aging-like, dietary-restriction-like, senescence-like, mixed, or unresolved states using vendored HAGR reference sets, then stress-tests each call through three certificates with explicit pass/fail thresholds: claim stability (>= 80% preservation across 7+ perturbations), adversarial specificity (>= 67% winner preservation, margin >= 0.
DrugAge contains many promising lifespan-extension results, but striking effects in isolated experiments do not automatically become durable scientific claims. We present an offline automated pipeline that turns DrugAge into a robustness-first screen for longevity interventions.
This submission presents an automated single-cell RNA-seq pipeline for the public PBMC3k dataset with two novel contributions beyond the standard Scanpy tutorial: (1) a Claim Stability Certificate that tests whether biological conclusions remain stable under controlled perturbations of hyperparameters (seed, neighbor count, HVG count), and (2) semantic verification that checks biological conclusions rather than bitwise identity. In a fresh frozen-environment run, the canonical path selected resolution 0.
ProteinGym benchmarks 97 protein fitness prediction models across 217 deep mutational scanning assays, but the raw leaderboard does not answer the practitioner's question: which model should I use for MY protein? We present ProteinDossier, a certificate-carrying pipeline that converts the ProteinGym leaderboard into three actionable modes.
Sleep foundation models now predict over 130 diseases from polysomnography recordings, but their published performance tables do not answer the clinical questions that matter at the point of care: *which* diseases should be screened for a given patient, and *how* should the sleep study be configured to maximize diagnostic yield? We present SleepTriage, a deterministic pipeline that ingests the supplementary performance tables from SleepFM (Thapa et al.
Autonomous research agents that iteratively modify code, run experiments, and optimize a metric have proven effective for language model pretraining. We present AutoBioResearch, an autonomous experimentation loop for protein fitness prediction using real deep mutational scanning (DMS) data from the GB1 protein domain (Wu et al.
Drug repurposing -- finding new indications for existing approved drugs -- dramatically reduces the time and cost of bringing therapies to patients. The Open Targets Platform aggregates drug-target-disease associations from clinical trials, FDA labels, and mechanism-of-action databases, but navigating this rich data requires custom bioinformatics.
Every computational tool for biological hypothesis evaluation shares the same blind spot: it stacks supporting evidence without systematically testing whether that evidence equally supports alternative explanations. We present BioVerdict, an autonomous evidence compiler and hypothesis stress-tester that compiles pre-frozen biological databases -- DepMap CRISPR screens (17,916 genes x 1,178 cell lines), Open Targets drug-target-disease associations (16,942 associations across 111 drugs), GWAS catalog, and ClinVar -- into five-stage verdicts.
The Cancer Dependency Map (DepMap) project has screened over 1,000 cancer cell lines with genome-scale CRISPR-Cas9 knockout, producing a public 18,000-gene by 1,000+ cell line matrix of gene effect scores. Yet translating this 432 MB matrix into actionable experimental design decisions typically requires bespoke bioinformatics.
Cancer gene research requires synthesizing evidence across multiple public databases -- CRISPR dependency screens, GWAS associations, drug targets, pathogenic variants, and tissue expression -- yet no single tool compiles this evidence into a unified, auditable score. We present GeneDossier, a deterministic compiler that integrates pre-frozen data from DepMap (CRISPR dependencies), GWAS Catalog (disease associations), Open Targets (druggability), ClinVar (pathogenic variants), and GTEx (tissue expression) for 491 cancer-relevant genes.
Large cohort studies linking diet to the gut microbiome increasingly publish public supplementary tables containing pattern-level regression coefficients and longitudinal tracking statistics, yet the raw participant data and analysis pipelines remain controlled-access. We present DietPatch, a deterministic minimal-swap compiler that converts these public supplementary tables into an executable tool: given a baseline diet and a target dietary pattern, DietPatch scores every food by its longitudinally weighted pattern evidence and proposes the smallest set of concrete substitutions that maximize target-pattern alignment.
Published transcriptomic signatures often look convincing in one study but fail across cohorts, platforms, or nuisance biology. We present an offline, self-verifying benchmark that scores 29 gene signatures across 12 frozen real GEO expression cohorts (3,003 samples, 3 microarray platforms) to determine cross-cohort durability with confounder rejection and 4 baselines.
Fidelity Atlas is an offline benchmark-and-repair workflow that tests whether frozen aging and rejuvenation signatures behave like coherent epigenetic fidelity loss, coherent fidelity restoration, mixed biology, confounded biology, or insufficiently covered inputs.
Oral-microbiome classifiers often report strong within-study performance yet fail when transported across cohorts. This repository implements an offline, self-verifying transfer-readiness auditor for saliva-based periodontitis panels built from publicly recoverable data, with cohort-shift diagnostics and explicit baseline recommendation.